Tics
- Sudden, rapid, recurrent, nonrhythmic motor movement or vocalization that is experienced as involuntary but can often be temporarily suppressed.
- Typical onset between ages 4–6 years and are preceded by a premonitory urge
- Transient tics affect up to 20% of children; persistent tic disorders and Tourette syndrome are less common (0.3–1.5%)
Classification
Tics are categorized as simple or complex:
- Simple motor tics: eye blinking, facial grimacing, shoulder shrugging, head jerking
- Simple vocal tics: throat clearing, sniffing, grunting
- Complex motor tics: coordinated movements appearing purposeful (e.g., simultaneous head turn and shoulder shrug), echopraxia
- Complex vocal tics: repeating words (echolalia, palilalia), or rarely coprolalia
DSM-5 diagnostic hierarchy
- Provisional tic disorder: motor and/or vocal tics for < 1year
- Persistent (chronic) tic disorder: motor or vocal tics (not both) for >/= 1 year
- Tourette syndrome >/= 2 motor tics adn >/= 1 vocal tic for >/= 1 year.
When to treat
- Not all tics require treatment.
- Intervention is indicated when tics cause functional impairment, physical discomfort, or psychosocial distress (embarrassment, bullying).
- Watchful waiting with psychoeducation is appropriate for mild, non-impairing tics.
Treatment approach
Behavioral therapy (first-line)
Comprehensive Behavioral Intervention for Tics (CBIT) is the only treatment rated with high confidence for efficacy by the AAN and is recommended before pharmacotherapy.
- Includes habit reversal training (awareness of premonitory urge + competing response),
- Relaxation techniques
- Functional interventions.
- Reduces tic severity by 26–31% and treatment gains are maintained for ≥6 months in children aged ≥9 years.
- Efficacy appears comparable to pharmacotherapy.
Pharmacotherapy (when behavioral therapy is insufficient or unavailable)
- First-line: Alpha-2 agonists — guanfacine and clonidine have moderate evidence and a favorable side-effect profile (sedation, hypotension); preferred as initial medication in children. Particularly useful when comorbid ADHD is present.
- Second-line: Atypical antipsychotics — aripiprazole, risperidone, and tiapride have evidence for tic reduction but carry risks of metabolic syndrome and tardive dyskinesia.
- Third-line: Typical antipsychotics — haloperidol and pimozide are effective but reserved for refractory cases due to significant adverse effects (extrapyramidal symptoms, QT prolongation).
Comorbidities are common and should be assessed: ADHD (alpha-2 agonists can treat both), OCD (SSRIs or CBT with exposure/response prevention), anxiety, and learning difficulties.